Hajiaghamohammadi Aliakbar, Samimi Rasoul, Miroliaee Arash, Kazemifar Amir Mohammad, Nazem Masoumeh
Qazvin university of medical sciences.
Glob J Health Sci. 2014 Nov 17;7(3):75-81. doi: 10.5539/gjhs.v7n3p75.
Hepatitis C virus (HCV) infection is universal. Side effects of its treatment are observed in many patients. The present study was designed to evaluate treatment outcome and side effects of the treatment in chronic HCV infection.
MATERIALS & METHODS: The current study was conducted prospectively on patients with hepatitis C infection. They had been treated with the standard drug regimen, if indicated. They were followed for treatment response, side effects of therapy, and its related factors.
From ninety one patients, eighty four persons finished their treatment course. They comprised 71 (84.5%) males and 13 (15.5%) females. Their mean age was 41.5 ± 11.90 years (20-69 years). Genotype 3 was the most common virus genotype (51.2%). Sustained virologic response (SVR) was 84.5% for genotype 3 and 47.5% for genotype 1. Decrease in hemoglobin (43%), weakness and fatigue (26%), neutropenia (13%), and thrombocytopenia (13%) were the most common side effects of the treatment. Seven patients can not finish their treatment course, because of the side effects.
Genotype 3, viral load less than 600000, and more than 3- fold rise in AST are associated with higher SVR. Early administration of the added drugs such as erythropoietin and G-CSF to not reduce the drug doses were also influential.
丙型肝炎病毒（HCV）感染普遍存在。许多患者在其治疗过程中会出现副作用。本研究旨在评估慢性HCV感染的治疗结果及治疗中的副作用。
本研究对丙型肝炎感染患者进行了前瞻性研究。如有指征，他们接受了标准药物治疗方案。对他们进行随访，观察治疗反应、治疗副作用及其相关因素。
91例患者中，84例完成了治疗疗程。其中男性71例（84.5%），女性13例（15.5%）。他们的平均年龄为41.5±11.90岁（20 - 69岁）。基因3型是最常见的病毒基因型（51.2%）。基因3型的持续病毒学应答（SVR）为84.5%，基因1型为47.5%。血红蛋白降低（43%）、虚弱和疲劳（26%）、中性粒细胞减少（13%）以及血小板减少（13%）是治疗最常见的副作用。7例患者因副作用未能完成治疗疗程。
基因3型、病毒载量低于600000以及天门冬氨酸氨基转移酶（AST）升高超过3倍与较高的SVR相关。早期给予促红细胞生成素和粒细胞集落刺激因子（G - CSF）等附加药物且不减少药物剂量也有影响。
